Sanofi is aiming to price its messenger RNA-based COVID-19 vaccine, NVX-CoV2373, at less than $12.20 (10 euros) per dose and said it will finalize the price after it releases the results of its phase 1/2 trial.

“We anticipate being able to determine a final price at the time of our phase 3 trials when we can confirm the final dosage,” a Sanofi spokesperson said.

Sanofi and GlaxoSmithKline began the phase 1/2 study of their jointly developed vaccine candidate in September. The companies expect to release preliminary results within weeks and also plan to launch a phase 3 trial.  They anticipate seeking regulatory approval for the vaccine during the first half of 2021.